**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 9803**

**Columns:** **TOPIC HIGHLIGHTS**

**WJG 20th Anniversary Special Issues (8): Gastric cancer**

**New approaches to gastric cancer staging: Beyond endoscopic ultrasound, computed tomography and positron emission tomography**

Yoon H *et al*. Gastric cancer staging

Hyuk Yoon, Dong Ho Lee

**Hyuk Yoon**, **Dong Ho Lee**, Department of Internal Medicine,Seoul National University Bundang Hospital, Seoungnam, 463-707 Gyeonggi-do, South Korea

**Dong Ho Lee**, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 110-744 Seoul, South Korea

**Author contributions**: Lee DH designed the review paper, revised the manuscript, and approved the final version; Yoon H collected the data and wrote the paper.

**Corresponding author:** **Dong Ho Lee, MD,** Department of Internal Medicine,

Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam, 463-707 Gyeonggi-do, South Korea. dhljohn@yahoo.co.kr

**Telephone:** +82-31-7877006 **Fax:** +82-31-7874051

**Received:** Feburary 28, 2014 **Revised:** April 16, 2014

**Accepted:** May 25, 2014

**Published online:**

**Abstract**

Currently, there is no single gold standard modality for staging of gastric cancer and several methods have been used complementarily in the each clinical situation. To make up for the shortcomings of conventional modalities such as endoscopic ultrasound, computed tomography and 18F-fluoro-2-deoxyglucose positron emission tomography, numerous attempts with new approaches have been made for gastric cancer staging. For T staging, magnifying endoscopy with narrow-band was evaluated to differentiate mucosal cancer from submucosal cancer. Single/double contrast-enhanced ultrasound and diffusion-weighted magnetic resonance imaging were also tried to improve diagnostic accuracy of gastric cancer. For intraoperative staging with sentinel node mapping, indocyanine green infrared and fluorescence imaging was introduced. In addition, to detect micrometastasis, real-time reverse transcription-polymerase chain reaction system with multiple markers was studied. Staging laparoscopy using 5-aminolevulinic acid-mediated photodynamic diagnosis and percutaneous diagnostic peritoneal lavage were also evaluated. However, most studies reporting new staging methods is preliminary and further studies for validation in clinical practice is needed. In this mini-review, we discuss new progress in gastric cancer staging. Especially, we focus on new diagnostic approach to gastric cancer staging beyond the conventional modalities and briefly review the remarkable clinical results of the studies published over the past three years.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Gastric cancer; Neoplasm staging; Diagnostic accuracy; New methods; New approaches

**Core tip:** Currently, there is no single gold standard modality for staging of gastric cancer. To make up for the shortcomings of conventional modalities or to replace these traditional methods, numerous attempts with new approaches such as magnifying endoscopy with narrow-band imaging, single/double contrast-enhanced ultrasound, and diffusion-weighted magnetic resonance imaging have been made for gastric cancer staging. In addition, for intraoperative staging, several newer methods associated with sentinel node mapping and diagnostic laparoscopy have been studied. However, most studies reporting new staging methods are preliminary and further studies for validation in clinical practice are needed.

Yoon H, Lee DH. New approaches to gastric cancer staging: Beyond endoscopic ultrasound, computed tomography and positron emission tomography. *World J Gastroenterol* 2014; In press

**Introduction**

Gastric cancer remains the second leading cause of cancer death worldwide[1]. Accurate staging of gastric cancer is pre-requisite to determine the most appropriate therapy. However, each modality which is currently used has limitations and no single staging modality has been accepted as the standard. Therefore, National Comprehensive Cancer Network practice guidelines for gastric cancer do not recommend specific modalities and suggest using a variety of techniques complementarily as staging work-up[2]. Currently, endoscopic ultrasound (EUS), computed tomography (CT), and 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) have been mainly used for staging modality of gastric cancer[3]. For T staging of gastric cancer, EUS has been established as the diagnostic modality of choice with pooled accuracy of 75%[4]. Due to the development of imaging techniques such as multi-detector row CT (MDCT)[5] and virtual gastroscopy by multi-planar reconstruction of images[6], CT may achieve similar diagnostic accuracy in T staging to EUS. However, the diagnostic accuracy for T staging of these two modalities is usually less than 80%-90%[7]. For N staging, the diagnostic performance of EUS is less reliable than for T-staging; pooled accuracy was 64% with sensitivity/specificity of 74%/80%[4]. For M staging, FGD-PET/CT has been gaining more attention due to the high sensitivity for distant metastasis. Recent study reported that FDG-PET/CT identifies radiographically occult metastasis in approximately 10% of patients with locally advanced gastric cancer[8]. However, the sensitivity of PET for peritoneal carcinomatosis is only approximately 50%[9]. Taken together, current staging modalities of gastric cancer have many limitations.

In this mini-review, we discuss the new progress in gastric cancer staging. Especially, we focus on new diagnostic approach to gastric cancer staging beyond the conventional modalities and briefly review the remarkable clinical results of the studies published over the past three years.

**Esophagogastroduodenoscopy**

Esophagogastroduodenoscopy (EGD) has been usually used for detection and diagnosis of gastric cancer rather than staging of gastric cancer. However, for the pure purpose of prediction of depth of invasion of early gastric cancer (EGC) (T1a *vs* T1b), EGD was found to provide reliable accuracy (overall accuracy: 78.0%-79.0%) and may be an alternative method of EUS[10,11]. Recently, Kubota *et al* first reported the usefulness of computer-aided diagnosis of gastric cancer invasion on endoscopic images[12]. The authors investigated the efficacy of T staging of gastric cancer on endoscopic images using computer-aided pattern recognition about 344 patients who underwent gastrectomy or endoscopic resection. Although the overall diagnostic accuracy was 64.7% due to the relatively lower accuracy for advanced T staging, the diagnostic accuracy and positive predictive value in the T1 staging was nearly equal to that obtained by endoscopic diagnosis (77.2% and 80.1%, respectively). Even though this is a primitive study, this modality has unique and remarkable merit in that this might lead to standardization and globalization of medicine, since physicians are required to have no specialized techniques or special knowledge to make a diagnosis.

**MAGNIFYING ENDOSCOPY WITH NARROW-BAND IMAGING**

The development of magnifying endoscopy with narrow-band imaging (ME-NBI) has allowed simple and clear visualization of vascular architecture and surface structure of the superficial mucosa in the gastrointestinal tract[13]. In the field of gastric cancer, many studies demonstrated the usefulness of ME-NBI in distinguishing EGC from noncancerous lesions, evaluation of histologic types of EGC, and determination of tumor margin in EGC[14-16]. However, whether ME-NBI is useful in predicting depth of invasion in EGC is unclear. In Asian-Pacific consensus which was published in 2011, a panel of experts denied the statement that ME-NBI is useful in predicting depth of gastric cancer[17]. The panel reasoned that unlike superficial esophageal squamous carcinoma, for EGC the invasive tissue is often not exposed at the surface and mucosal structure remains, even when cancer invades the submucosa; therefore it is difficult to estimate reliably the depth of invasion by surface appearance only. However, thereafter, several studies have reported positive results on this subject. Li *et al*[18] classified ME-NBI findings of suspected gastric lesions into 3 types: clear regular (type A), obscure irregular (type B), and no (type C) surface patterns and microvascular architecture. When a lesion was classified into type B or C pattern, the sensitivity, specificity, positive predictive value, and negative predictive value predicting deep submucosal invasion more than sm1 in EGC was 72.7%, 80.5%, 50.0%, and 91.7%, respectively; the total accuracy was 78.9% (95%CI: 66.0%-87.8%). Kobara *et al* reported that ME-NBI findings of non-structure, scattery vessels and multi-caliber vessels can possibly serve as indicators of deep submucosal invasion in differentiated and depressed-type of EGC[19]. Kikuchi *et al*[20] showed that when the presence of dilated vessels was considered a diagnostic criterion for submucosal EGC, diagnostic accuracy, sensitivity, and specificity were 81.5%, 37.5%, and 88.3%, respectively. Yagi *et al*[21] suggested that in multivariate logistic regression analysis ME-NBI findings of a blurry mucosal pattern (OR = 12.15, 95%CI: 3.45-42.76, *P* = 0.000) and an irregular mesh pattern (OR = 22.55, 95%CI: 4.22-120.45, *P* = 0.000) were independent predictors of submucosal invasion in differentiated EGC. However, several limitations in these studies were also pointed out[22]. First, the absolute number of reports is too small to reach any kind of significance or consensus. Second, mostly the depressed and differentiated types of EGC have been studied. Third, applied criteria of ME-NIB to evaluate the depth of invasion varied according to the studies and inter-observe agreement of ME-NIB findings for these criteria was not certainly validated. In addition, some studies focused on differentiation between T1a and T1b and others tried to distinguish sm1 EGC from sm2/3 EGC. Nevertheless, because it is very important to predict depth of invasion in EGC to decide whether it could be treated by ESD or not[23,24], the usefulness of ME-NBI in T staging of EGC deserves further investigation.

**contrast-enhanced ultrasound**

Conventional abdominal ultrasound is an attractive diagnostic method because of its general availability, simplicity and non-invasiveness. However, the value of this modality in staging of gastric cancer remains unclear and there are limited numbers of published studies. This is mainly originated from the relatively low diagnostic accuracy of T staging compared with other modalities[25]. Double contrast-enhanced ultrasound is a transabdominal ultrasound technique using both intravenous and intraluminal contrast to enhance sonographic visualization. Recently, Zheng *et al*[26] compared retrospectively the staging accuracy of double contrast-enhanced ultrasound with EUS in the 162 gastric cancer patients. Double contrast-enhanced ultrasound was comparable to EUS in tumor depth evaluation (overall accuracy for T staging: 77.2% *vs* 74.7%) and superior to EUS in N staging (overall accuracy: 78.4% *vs* 57.4%, *P* = 0.001).

Very few studies have addressed the role of contrast-enhanced ultrasound (CEUS) using intravenous injection of microbubble contrast media in detection of metastatic gastric cancer. Most studies regarding the usefulness of CEUS for detection of metastatic cancer have been for liver metastases, since CT has limitations to detect and characterize subcentimetric liver lesions. Although it was not gastric cancer-specific study, Piscaglia *et al*[27] reported that CEUS is more sensitive than conventional ultrasound in the detection of liver metastases and could be complementarily used with CT to achieve maximum sensitivity in M staging of gastrointestinal cancer. Recently, Laghi *et al*[28] reported that CEUS can be helpful in demonstrating or excluding metastases in cancer patients with subcentimetric, indeterminate focal liver lesions detected by MDCT. The authors applied CEUS to the patients in whom ultrasound failed to recognize any abnormality or cystic imaging for indeterminate focal liver lesions by MDCT. CEUS recognized additional liver metastases in 8 cases, but it failed to detect 3 metastatic and benign lesions. In addition, this study also was not gastric-cancer specific; gastric cancer was the primary cancer only in 11 among 132 subjects. However, because single or double contrast-enhanced ultrasounds are noninvasive modalities, they deserve to be evaluated for the staging of gastric cancer.

**Contrast-enhanced endoscopic ultrasound**

Although contrast-enhanced EUS was introduced in the early 1990s, most reports have been regarding pancreatic lesions[29,30]. By contrast, the role of contrast-enhanced EUS in gastric cancer staging is unclear. Already more than 10 years ago, Nomura *et al*[31] performed EUS and additional contrast-enhanced EUS for 30 gastric cancers and reported that diagnostic accuracy for T staging of gastric cancer improved from 76.7% for EUS to 90% for contrast-enhanced EUS. However, we could not find other articles on this subject, thereafter. Further studies are strongly required.

**magnetic resonance imaging ing**

Even though there have been only a few studies regarding the usefulness of magnetic resonance imaging (MRI) for gastric cancer staging, meta-analysis showed that MRI had higher accuracy for T staging (83%) and similar accuracy for N staging (53%) compared to other staging modalities such as CT and PET[25].

Recently, diffusion-weighted (DW) MRI which had been generally utilized in the early diagnosis of brain ischemia has been studied in the diagnosis of solid tumor. DW-MRI applies a pair of diffusion-weighted gradient pulses to generate signals that are sensitive to localized water diffusibility and thus permit the cellular density of the tissue to be indirectly measured[32]. In cancerous tissues, the Brownian motion of water molecules is confined as a result of the reduced interspace caused by proliferated cells and interstitial substances[33]. Therefore, cancerous tissues display higher signal intensity on DW-MRI than normal tissue. For diagnosis of gastric cancer, Shinya *et al*[34] first suggested the potential efficacy of DW-MRI in a pilot study on 15 patients. Thereafter, Zhang *et al*[35] showed the addition of DW imaging to T1/T2-weighted MRI could more exactly differentiate Borrmann type IV advanced gastric cancer from poorly distended stomach wall. Recently, Liu S *et al*[36] reported the usefulness of DW-MRI in T staging of gastric cancer on larger subjects. When two radiologists independently interpreted T2-weighted, contrast-enhanced and DW-MRI in 51 patients with gastric cancer, the addition of DW-MRI significantly increased overall accuracy of T staging (76.5% *vs* 88.2%, *P* = 0.031). The authors emphasized that DW-MRI could overcome the over-estimation problem of T staging in advanced gastric cancer. However, the staging accuracy of DW-MRI for EGC was relatively low in this study. In addition, the stating criteria using DW-MRI has not been unified. Therefore, to prove the diagnostic efficacy of DW-MRI on gastric cancer staging, validation studies on larger subjects are required.

**Sentinel node mapping**

In countries like Korea and Japan where the rate of EGC is relatively high, minimally invasive gastric surgeries have been performed increasingly. Laparoscopic function-preserving gastrectomy including partial gastrectomy, segmental gastrectomy, and proximal gastrectomy would be expected to increase patients’ quality of life by reducing late complications of gastric surgery, such as dumping syndrome and body weight loss. However, because function-preserving gastrectomy are performed with limited stomach resection and lymph node dissection, the absence of skip metastasis in the 2nd or 3rd compartment of regional lymph nodes is prerequisite to apply these procedures widely. To solve this problem, sentinel node (SN) mapping which is a novel diagnostic tool for the identification of clinically undetectable lymph node metastasis and SN navigation surgery based on SN mapping have been studied in patients with EGC[37]. Clinical application and validity of SN mapping in patients with EGC has been a controversial issue for years. However, a recent meta-analysis on 38 studies including 2128 patients demonstrated acceptable diagnostic accuracy of SN mapping for lymph node status[38]. The authors of this meta-analysis reported that pooled SLN identification rate, sensitivity, negative predictive value, and accuracy were 93.7%, 76.9%, 90.3%, and 92.0%, respectively.

Sentinel node mapping and SN navigation surgery are gaining more and more supporting evidence for possible therapeutic option for early gastric cancer, especially cT1N0M0. However, further studies are needed to confirm the best procedure and standard criteria. At present, dual-tracer method with a radioactive colloid and blue dye is considered the most reliable method for SN mapping. Sentinel node detection rate with this method was reported as high as 97.5%[39]. By contrast, SN detection rate of other modalities like preoperative imaging of SNs using CT lymphography is still relatively lower than with conventional dual-tracer method[40]. Several newer methods like indocyanine green (ICG) infrared imaging[41] and ICG fluorescence imaging[42] have been introduced to improve the accuracy of SN detection by endoscopic dye-tracer.

Although the clinical significance of micrometastasis including isolated tumor cells in SNs of patients with EGC remains unclear[43], histopathology and molecular analysis methods to detect micrometastasis in these patients have been steadily studied. The two main methods for detection of lymph node micrometastasis are immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR). Recently, Shimizu *et al*[44] reported a more rapid and sensitive real-time RT-PCR system with multiple markers (cytokeratin-19, cytokeratin-20, and carcinoembryonic antigen) to detect micrometastasis. The authors showed that 27 % (28/103 patients) of EGC had negative histopathological but positive RT-PCR findings. However, the time (80 min) to gain results is still too long to use in the intraoperative diagnosis of SN and more studies are needed to improve this problem. Yano *et al*[45] recently compared the efficacy of ICG and infrared ray laparoscopy system with immunohistochemistry for anti-cytokeratin antibody in SN navigation surgery. In 130 patients with early gastric cancer, immunohistochemistry staining additionally detected 15 patients with micrometastasis compared with hematoxylin and eosin staining (31 patients *vs* 16 patients). However, all 27 lymph nodes in these patients with metastasis by immunohistochemistry staining but not by hematoxylin and eosin staining were micrometastasis or less and included in the SN. Therefore, the authors concluded that ICG-positive lymphatic basin dissection by SN navigation surgery with infrared ray observation seems to be an adequate method of lymph node dissection for gastric cancer.

**Diagnostic laparoscopy**

FDG-PET has been suggested appropriate staging modality for distant metastases. The sensitivity/specificity of FDG-PET for detection of metastatic lymph node and distant metastasis were reported as 21%-40%/89%-100% and 35%-74%/74%-99%, respectively[46]. However, FDG-PET has limitations such as frequent false-negative cases in signet-ring cell carcinoma and the lack of a unified criteria in how to interpret for management decisions[47]. Therefore, patients with incurable or unresectable gastric cancer are still subjected to non-therapeutic laparotomy. To solve this problem, diagnostic laparoscopy has been advocated by some to be essential in decision-making in advanced gastric cancer[48]. However, large retrospective series have demonstrated the yield of diagnostic laparoscopy in staging locally advanced gastric cancer to range from 13% to 40%[49].

For recent years, several new approaches regarding diagnostic laparoscopy have been published. Positive peritoneal cytology has been shown to be an independent predictor for disease recurrence after curative resection and poor overall survival[50,51]. Positive peritoneal cytology confers the same prognosis as clinical stage IV disease in gastric cancer. Therefore, it has been included in the seventh edition of the American Joint Committee on Cancer staging manual as M1 disease[52]. However, the sensitivity of conventional cytology examination is lower than 60% due to sampling error[53,54]. To overcome this problem, several studies have evaluated the clinical significance of RT-PCR in peritoneal lavage fluid in gastric cancer[55-57]. These studies have demonstrated the increased sensitivity of RT-PCR when compared to cytology for the detection of peritoneal cancer cells. However, these studies have been carried in Asia and in the setting of metastatic disease. Recently, Wong *et al*[58] additionally demonstrated that RT-PCR for carcinoembryonic antigen increases the detection of subclinical peritoneal disease and is more sensitive than cytology in curatively resected patients at a single Western institution. They collect peritoneal lavage samples prospectively from 156 patients with biopsy-proven gastric cancer undergoing staging laparoscopy. These washings were analyzed by both Papanicolaou staining and RT-PCR for the carcinoembryonic antigen. Among 118 patients in whom peritoneal disease was not visible at laparoscopy, the rate of PCR-positive was higher than that of cytology-positive (24% *vs* 7%).

Recently, two pilot studies regarding staging laparoscopy using 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis in advanced gastric cancers were reported in Japan[59,60]. 5-ALA is an endogenous substance and a natural precursor of the heme pathway. Orally administered 5-ALA is metabolized and accumulated as protoporphyrin IX, which is a photosensitizer. 5-ALA is immediately metabolized to heme in normal cells. On the other hand, since the activity of porphobilinogen deaminase is high in abnormal cells and the activity of ferrochelatase is low, protoporphyrin IX accumulates in the mitochondria in cancer cells[61]. Oral 5-ALA and intravesically applied 5-ALA derivative have been approved as an optical imaging agent for the enhancement of the intraoperative detection of malignant glioma and bladder cancer, respectively in Europe[62]. However, only a few experimental cases for gastric cancer patients have been reported[63]. Kishi *et al*[59] performed staging laparoscopy using 5-ALA photodynamic diagnosis in 13 patients with serosa-invading advanced gastric cancer, and the detection sensitivity of 5-ALA photodynamic diagnosis was compared to the observations using conventional white light. The tumor detection rate using 5-ALA photodynamic diagnosis was significantly higher than the detection rate using white light (72% *vs* 39%, *P* < 0.001). Murayama *et al*[60] also applied the same methods in 13 patients with advanced gastric cancer. The accuracy of the fluorescence imaging was greater than that of the white light imaging (100% *vs* 85.7%). In both studies, there were no acute or major complications. These two studies demonstrated that staging laparoscopy with 5-ALA photodynamic diagnosis is safe and improved the diagnostic accuracy for peritoneal metastases in patients with gastric cancer. However, further clinical trials in larger number of subjects are required to generalize the results of these studies.

Percutaneous diagnostic peritoneal lavage (DPL) was initially introduced as a procedure to determine the likelihood of peritoneal penetration and injury to the abdominal viscera in trauma patients. In large studies, DPL has been shown to be rapid, safe, and effective in this setting[64]. Typically, 1 L of saline is held above the patient and passively infused into the peritoneal cavity through a percutaneous catheter using the Seldinger technique. Following infusion, the empty bag is left to gravity and the effluent measured for red blood cells and bilirubin to determine the presence of solid organ injury. Patients with positive peritoneal cytology on DPL could be spared from a non-curative radical resection and have expedited access to systemic therapies. Based on this idea, Mezhir *et al*[65] studied whether DPL can be used to assess peritoneal cytology in patients with gastric cancer for the first time. Patients with gastric cancer were prospectively enrolled to undergo DPL prior to diagnostic laparoscopy. Saline was instilled through a percutaneous catheter and fluid was collected for cytology. Washings obtained during diagnostic laparoscopy were used as controls. The sensitivity and specificity of DPL was 92% (9/10 cases) and 100% (12/12 cases), respectively. However, there were six patients with negative DPL-cytology who had visible M1 disease diagnosed with diagnostic laparoscopy (DPL evaluation of M1 disease: sensitivity 54.5% and specificity 100%). In addition, DPL was not successful in all patients (technical failure rate: 18.5%). The authors concluded that DPL is a safe method of detecting positive cytology in patients with gastric cancer, however gross M1 disease may be missed without visual inspection. Because of above-mentioned limitations, a larger series of patients would be required to determine the optimal patient population for DPL and the specific role of DPL in the staging workup of patients with gastric cancer.

**OTHER nEW Approaches**

Cui *et al*[66] reported the first study on identification of genes whose expression patterns can serve as markers for overall cancer stages. Microarray gene-expression data of 54 paired gastric cancer and adjacent noncancerous gastric tissues were analyzed to establish gene signatures for cancer stages. The authors identified two signatures for cancer staging, consisting of 10 genes and 9 genes, respectively. These two genetic signatures provided high classification accuracies at 90.0% and 84.0%, among early (stage I+II) and advanced gastric cancer stages (stage III+IV), respectively. The expression patterns of these signature genes were successfully validated by other public dataset. In addition, the authors identified genes which consistently show high positive or negative correlation with different pathological stages (LANCL3, MFAP2 and PPA1).

So far, scoring systems have been frequently used to predict the outcome of patients with gastric cancer[67-69]. However, most of these prognostic scoring systems took into account the postoperative pathologic properties of the tumor, so they did not work during preoperative decision-making. To improve the estimation of tumor status and facilitate the stage-dependent treatment planning, Chet *et al*[70] suggested simple risk score system for prediction of TNM stages in gastric cancer. They prospectively collected clinicopathologic data from 108 curatively resected patients with gastric cancer. The risk score was established on the basis of independent predictive factors for tumor stages and its performance was evaluated by receiver operating characteristic (ROC) analysis. As a result, they found 4 independent factors (serum albumin levels, tumor size, T and N categories determined by helical CT). When a score at 7 was defined as the optimal cut point, the sensitivity and specificity for differentiating advanced stage (stage III+IV) from early stage (stage I+II) was 79.6% and 85.2%, respectively. The overall accuracy was 82.4% and the discriminative ability was also good (the area under the ROC curve, 0.861-0.965). Therefore, the authors suggested that since patients with the risk score ≥ 7 are strongly suspected of having advanced stage of gastric cancer, D2 lymphadenectomy combined with perioperative adjuvant therapy should be recommended for these patients to increase the likelihood of curative resection and reduce the risk of recurrence. However, this study has some limitations in that the authors used the fifth edition of the American Joint Committee on Cancer staging manual. In addition, to apply this risk sore in daily clinical practice, validating on another patient series is required.

**CONCLUSION**

At the present time, there is no single gold standard modality for staging of gastric cancer and several methods have been used complementarily in the each clinical situation. To make up for the shortcomings of conventional modalities such as EUS, CT, and PET-CT or to replace these traditional methods, numerous attempts with new approaches have been made for gastric cancer staging. In addition, for intraoperative staging, several newer methods associated with SN mapping and diagnostic laparoscopy have been studied. However, most studies reporting new staging methods are preliminary and further studies for validation in clinical practice are needed.

**REFERENCECES**

1 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

2 **Ajani JA**, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G. Gastric cancer. *J Natl Compr Canc Netw* 2010; **8**: 378-409 [PMID: 20410333]

3 **Shen L**, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. *Lancet Oncol* 2013; **14**: e535-e547 [PMID: 24176572 DOI: 10.1016/s1470-2045(13)70436-4]

4 **Cardoso R**, Coburn N, Seevaratnam R, Sutradhar R, Lourenco LG, Mahar A, Law C, Yong E, Tinmouth J. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. *Gastric Cancer* 2012; **15 Suppl 1**: S19-S26 [PMID: 22237654 DOI: 10.1007/s10120-011-0115-4]

5 **Kim JW**, Shin SS, Heo SH, Choi YD, Lim HS, Park YK, Park CH, Jeong YY, Kang HK. Diagnostic performance of 64-section CT using CT gastrography in preoperative T staging of gastric cancer according to 7th edition of AJCC cancer staging manual. *Eur Radiol* 2012; **22**: 654-662 [PMID: 21965037 DOI: 10.1007/s00330-011-2283-3]

6 **Furukawa K**, Miyahara R, Itoh A, Ohmiya N, Hirooka Y, Mori K, Goto H. Diagnosis of the invasion depth of gastric cancer using MDCT with virtual gastroscopy: comparison with staging with endoscopic ultrasound. *AJR Am J Roentgenol* 2011; **197**: 867-875 [PMID: 21940574 DOI: 10.2214/ajr.10.5872]

7 **Kwee RM**, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. *J Clin Oncol* 2007; **25**: 2107-2116 [PMID: 17513817 DOI: 10.1200/JCO.2006.09.5224]

8 **Smyth E**, Schöder H, Strong VE, Capanu M, Kelsen DP, Coit DG, Shah MA. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. *Cancer* 2012; **118**: 5481-5488 [PMID: 22549558 DOI: 10.1002/cncr.27550]

9 **Yoshioka T**, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, Yamaura G, Takahashi H, Fukuda H, Kanamaru R. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. *J Nucl Med* 2003; **44**: 690-699 [PMID: 12732669]

10 **Choi J**, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Comparison of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer. *Endoscopy* 2010; **42**: 705-713 [PMID: 20652857 DOI: 10.1055/s-0030-1255617]

11 **Choi J**, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Endoscopic prediction of tumor invasion depth in early gastric cancer. *Gastrointest Endosc* 2011; **73**: 917-927 [PMID: 21316050 DOI: 10.1016/j.gie.2010.11.053]

12 **Kubota K**, Kuroda J, Yoshida M, Ohta K, Kitajima M. Medical image analysis: computer-aided diagnosis of gastric cancer invasion on endoscopic images. *Surg Endosc* 2012; **26**: 1485-1489 [PMID: 22083334 DOI: 10.1007/s00464-011-2036-z]

13 **Hirata I**, Nakagawa Y, Ohkubo M, Yahagi N, Yao K. Usefulness of magnifying narrow-band imaging endoscopy for the diagnosis of gastric and colorectal lesions. *Digestion* 2012; **85**: 74-79 [PMID: 22269282 DOI: 10.1159/000334642]

14 **Kaise M**, Kato M, Urashima M, Arai Y, Kaneyama H, Kanzazawa Y, Yonezawa J, Yoshida Y, Yoshimura N, Yamasaki T, Goda K, Imazu H, Arakawa H, Mochizuki K, Tajiri H. Magnifying endoscopy combined with narrow-band imaging for differential diagnosis of superficial depressed gastric lesions. *Endoscopy* 2009; **41**: 310-315 [PMID: 19340733 DOI: 10.1055/s-0028-1119639]

15 **Nakayoshi T**, Tajiri H, Matsuda K, Kaise M, Ikegami M, Sasaki H. Magnifying endoscopy combined with narrow band imaging system for early gastric cancer: correlation of vascular pattern with histopathology (including video). *Endoscopy* 2004; **36**: 1080-1084 [PMID: 15578298 DOI: 10.1055/s-2004-825961]

16 **Kiyotoki S**, Nishikawa J, Satake M, Fukagawa Y, Shirai Y, Hamabe K, Saito M, Okamoto T, Sakaida I. Usefulness of magnifying endoscopy with narrow-band imaging for determining gastric tumor margin. *J Gastroenterol Hepatol* 2010; **25**: 1636-1641 [PMID: 20880172 DOI: 10.1111/j.1440-1746.2010.06379.x]

17 **Uedo N**, Fujishiro M, Goda K, Hirasawa D, Kawahara Y, Lee JH, Miyahara R, Morita Y, Singh R, Takeuchi M, Wang S, Yao T. Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region. *Dig Endosc* 2011; **23 Suppl 1**: 58-71 [PMID: 21535204 DOI: 10.1111/j.1443-1661.2011.01119.x]

18 **Li HY**, Dai J, Xue HB, Zhao YJ, Chen XY, Gao YJ, Song Y, Ge ZZ, Li XB. Application of magnifying endoscopy with narrow-band imaging in diagnosing gastric lesions: a prospective study. *Gastrointest Endosc* 2012; **76**: 1124-1132 [PMID: 23025977 DOI: 10.1016/j.gie.2012.08.015]

19 **Kobara H**, Mori H, Fujihara S, Kobayashi M, Nishiyama N, Nomura T, Kato K, Ishihara S, Morito T, Mizobuchi K, Iwama H, Masaki T. Prediction of invasion depth for submucosal differentiated gastric cancer by magnifying endoscopy with narrow-band imaging. *Oncol Rep* 2012; **28**: 841-847 [PMID: 22752002 DOI: 10.3892/or.2012.1889]

20 **Kikuchi D**, Iizuka T, Hoteya S, Yamada A, Furuhata T, Yamashita S, Domon K, Nakamura M, Matsui A, Mitani T, Ogawa O, Watanabe S, Kaise M. Usefulness of magnifying endoscopy with narrow-band imaging for determining tumor invasion depth in early gastric cancer. *Gastroenterol Res Pract* 2013; **2013**: 217695 [PMID: 23401676 DOI: 10.1155/2013/217695]

21 **Yagi K**, Saka A, Nozawa Y, Nakamura A, Umezu H. Prediction of submucosal gastric cancer by narrow-band imaging magnifying endoscopy. *Dig Liver Dis* 2014; **46**: 187-190 [PMID: 24157380 DOI: 10.1016/j.dld.2013.09.003]

22 **Jang JY**. The Usefulness of Magnifying Endoscopy and Narrow-Band Imaging in Measuring the Depth of Invasion before Endoscopic Submucosal Dissection. *Clin Endosc* 2012; **45**: 379-385 [PMID: 23251885 DOI: 10.5946/ce.2012.45.4.379]

23 **Gotoda T**, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. *Gastric Cancer* 2000; **3**: 219-225 [PMID: 11984739]

24 **Kojima T**, Parra-Blanco A, Takahashi H, Fujita R. Outcome of endoscopic mucosal resection for early gastric cancer: review of the Japanese literature. *Gastrointest Endosc* 1998; **48**: 550-54; discussion 550-54; [PMID: 9831855 DOI: S0016510798003320]

25 **Seevaratnam R**, Cardoso R, McGregor C, Lourenco L, Mahar A, Sutradhar R, Law C, Paszat L, Coburn N. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. *Gastric Cancer* 2012; **15 Suppl 1**: S3-18 [PMID: 21837458 DOI: 10.1007/s10120-011-0069-6]

26 **Zheng Z**, Yu Y, Lu M, Sun W, Wang F, Li P, Zhang Y, Lin L, Huang P, Chen J, Zhang H, Xie Z, Dong Xda E. Double contrast-enhanced ultrasonography for the preoperative evaluation of gastric cancer: a comparison to endoscopic ultrasonography with respect to histopathology. *Am J Surg* 2011; **202**: 605-611 [PMID: 21824594 DOI: 10.1016/j.amjsurg.2010.09.033]

27 **Piscaglia F**, Corradi F, Mancini M, Giangregorio F, Tamberi S, Ugolini G, Cola B, Bazzocchi A, Righini R, Pini P, Fornari F, Bolondi L. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. *BMC Cancer* 2007; **7**: 171 [PMID: 17767722 DOI: 10.1186/1471-2407-7-171]

28 **Laghi F**, Catalano O, Maresca M, Sandomenico F, Siani A. Indeterminate, subcentimetric focal liver lesions in cancer patients: additional role of contrast-enhanced ultrasound. *Ultraschall Med* 2010; **31**: 283-288 [PMID: 20517816 DOI: 10.1055/s-0029-1245383]

29 **Hirooka Y**, Itoh A, Kawashima H, Ohno E, Itoh Y, Nakamura Y, Hiramatsu T, Sugimoto H, Sumi H, Hayashi D, Ohmiya N, Miyahara R, Nakamura M, Funasaka K, Ishigami M, Katano Y, Goto H. Contrast-enhanced endoscopic ultrasonography in digestive diseases. *J Gastroenterol* 2012; **47**: 1063-1072 [PMID: 23001249 DOI: 10.1007/s00535-012-0662-4]

30 **Kitano M**, Sakamoto H, Kudo M. Endoscopic ultrasound: contrast enhancement. *Gastrointest Endosc Clin N Am* 2012; **22**: 349-58, xi [PMID: 22632956 DOI: 10.1016/j.giec.2012.04.013]

31 **Nomura N**, Goto H, Niwa Y, Arisawa T, Hirooka Y, Hayakawa T. Usefulness of contrast-enhanced EUS in the diagnosis of upper GI tract diseases. *Gastrointest Endosc* 1999; **50**: 555-560 [PMID: 10502181]

32 **Cercignani M**, Horsfield MA. The physical basis of diffusion-weighted MRI. *J Neurol Sci* 2001; **186 Suppl 1**: S11-S14 [PMID: 11334985]

33 **Friedrich KM**, Matzek W, Gentzsch S, Sulzbacher I, Czerny C, Herneth AM. Diffusion-weighted magnetic resonance imaging of head and neck squamous cell carcinomas. *Eur J Radiol* 2008; **68**: 493-498 [PMID: 19189427]

34 **Shinya S**, Sasaki T, Nakagawa Y, Guiquing Z, Yamamoto F, Yamashita Y. The usefulness of diffusion-weighted imaging (DWI) for the detection of gastric cancer. *Hepatogastroenterology* ; **54**: 1378-1381 [PMID: 17708258]

35 **Zhang XP**, Tang L, Sun YS, Li ZY, Ji JF, Li XT, Liu YQ, Wu Q. Sandwich sign of Borrmann type 4 gastric cancer on diffusion-weighted magnetic resonance imaging. *Eur J Radiol* 2012; **81**: 2481-2486 [PMID: 22099950 DOI: 10.1016/j.ejrad.2011.10.021]

36 **Liu S**, He J, Guan W, Li Q, Yu H, Zhou Z, Bao S, Zhou Z. Added value of diffusion-weighted MR imaging to T2-weighted and dynamic contrast-enhanced MR imaging in T staging of gastric cancer. *Clin Imaging* 2013; **38**: 122-128 [PMID: 24411204 DOI: 10.1016/j.clinimag.2013.12.001]

37 **Takeuchi H**, Kitagawa Y. New sentinel node mapping technologies for early gastric cancer. *Ann Surg Oncol* 2013; **20**: 522-532 [PMID: 22941161 DOI: 10.1245/s10434-012-2602-1]

38 **Wang Z**, Dong ZY, Chen JQ, Liu JL. Diagnostic value of sentinel lymph node biopsy in gastric cancer: a meta-analysis. *Ann Surg Oncol* 2012; **19**: 1541-1550 [PMID: 22048632 DOI: 10.1245/s10434-011-2124-2]

39 **Kitagawa Y**, Takeuchi H, Takagi Y, Natsugoe S, Terashima M, Murakami N, Fujimura T, Tsujimoto H, Hayashi H, Yoshimizu N, Takagane A, Mohri Y, Nabeshima K, Uenosono Y, Kinami S, Sakamoto J, Morita S, Aikou T, Miwa K, Kitajima M. Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. *J Clin Oncol* 2013; **31**: 3704-3710 [PMID: 24019550 DOI: 10.1200/JCO.2013.50.3789]

40 **Tsujimoto H**, Yaguchi Y, Sakamoto N, Kumano I, Takahata R, Matsumoto Y, Yoshida K, Sugasawa H, Ono S, Ichikura T, Yamamoto J, Hase K. Computed tomography lymphography for the detection of sentinel nodes in patients with gastric carcinoma. *Cancer Sci* 2010; **101**: 2586-2590 [PMID: 20796000 DOI: 10.1111/j.1349-7006.2010.01706.x]

41 **Ohdaira H**, Nimura H, Mitsumori N, Takahashi N, Kashiwagi H, Yanaga K. Validity of modified gastrectomy combined with sentinel node navigation surgery for early gastric cancer. *Gastric Cancer* 2007; **10**: 117-122 [PMID: 17577622 DOI: 10.1007/s10120-007-0419-6]

42 **Tajima Y**, Yamazaki K, Masuda Y, Kato M, Yasuda D, Aoki T, Kato T, Murakami M, Miwa M, Kusano M. Sentinel node mapping guided by indocyanine green fluorescence imaging in gastric cancer. *Ann Surg* 2009; **249**: 58-62 [PMID: 19106676 DOI: 10.1097/SLA.0b013e3181927267]

43 **Arigami T**, Uenosono Y, Yanagita S, Nakajo A, Ishigami S, Okumura H, Kijima Y, Ueno S, Natsugoe S. Clinical significance of lymph node micrometastasis in gastric cancer. *Ann Surg Oncol* 2013; **20**: 515-521 [PMID: 22546997 DOI: 10.1245/s10434-012-2355-x]

44 **Shimizu Y**, Takeuchi H, Sakakura Y, Saikawa Y, Nakahara T, Mukai M, Kitajima M, Kitagawa Y. Molecular detection of sentinel node micrometastases in patients with clinical N0 gastric carcinoma with real-time multiplex reverse transcription-polymerase chain reaction assay. *Ann Surg Oncol* 2012; **19**: 469-477 [PMID: 22065193 DOI: 10.1245/s10434-011-2122-4]

45 **Yano K**, Nimura H, Mitsumori N, Takahashi N, Kashiwagi H, Yanaga K. The efficiency of micrometastasis by sentinel node navigation surgery using indocyanine green and infrared ray laparoscopy system for gastric cancer. *Gastric Cancer* 2012; **15**: 287-291 [PMID: 22041868 DOI: 10.1007/s10120-011-0105-6]

46 **Shimada H**, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of ¹⁸F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. *Gastric Cancer* 2011; **14**: 13-21 [PMID: 21331531 DOI: 10.1007/s10120-011-0017-5]

47 **Hopkins S**, Yang GY. FDG PET imaging in the staging and management of gastric cancer. *J Gastrointest Oncol* 2011; **2**: 39-44 [PMID: 22811826 DOI: 10.3978/j.issn.2078-6891.2010.004]

48 **Leake PA**, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, Law C, Coburn NG. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. *Gastric Cancer* 2012; **15 Suppl 1**: S38-S47 [PMID: 21667136 DOI: 10.1007/s10120-011-0047-z]

49 **Karanicolas PJ**, Elkin EB, Jacks LM, Atoria CL, Strong VE, Brennan MF, Coit DG. Staging laparoscopy in the management of gastric cancer: a population-based analysis. *J Am Coll Surg* 2011; **213**: 644-651, 651.e1 [PMID: 21872497 DOI: 10.1016/j.jamcollsurg.2011.07.018]

50 **Bentrem D**, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. *Ann Surg Oncol* 2005; **12**: 347-353 [PMID: 15915368 DOI: 10.1245/ASO.2005.03.065]

51 **La Torre M**, Ferri M, Giovagnoli MR, Sforza N, Cosenza G, Giarnieri E, Ziparo V. Peritoneal wash cytology in gastric carcinoma. Prognostic significance and therapeutic consequences. *Eur J Surg Oncol* 2010; **36**: 982-986 [PMID: 20591604 DOI: 10.1016/j.ejso.2010.06.007]

52 **Edge SB**, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer Staging Manual. New York: Springer, **2010**

53 **Abe S**, Yoshimura H, Tabara H, Tachibana M, Monden N, Nakamura T, Nagaoka S. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome. *J Surg Oncol* 1995; **59**: 226-229 [PMID: 7630168]

54 **Wilkiemeyer MB**, Bieligk SC, Ashfaq R, Jones DB, Rege RV, Fleming JB. Laparoscopy alone is superior to peritoneal cytology in staging gastric and esophageal carcinoma. *Surg Endosc* 2004; **18**: 852-856 [PMID: 15054656 DOI: 10.1007/s00464-003-8828-z]

55 **Yonemura Y**, Endou Y, Fujimura T, Fushida S, Bandou E, Kinoshita K, Sugiyama K, Sawa T, Kim BS, Sasaki T. Diagnostic value of preoperative RT-PCR-based screening method to detect carcinoembryonic antigen-expressing free cancer cells in the peritoneal cavity from patients with gastric cancer. *ANZ J Surg* 2001; **71**: 521-528 [PMID: 11527261]

56 **Wang JY**, Lin SR, Lu CY, Chen CC, Wu DC, Chai CY, Chen FM, Hsieh JS, Huang TJ. Gastric cancer cell detection in peritoneal lavage: RT-PCR for carcinoembryonic antigen transcripts versus the combined cytology with peritoneal carcinoembryonic antigen levels. *Cancer Lett* 2005; **223**: 129-135 [PMID: 15890245 DOI: 10.1016/j.canlet.2004.09.031]

57 **Oyama K**, Terashima M, Takagane A, Maesawa C. Prognostic significance of peritoneal minimal residual disease in gastric cancer detected by reverse transcription-polymerase chain reaction. *Br J Surg* 2004; **91**: 435-443 [PMID: 15048743 DOI: 10.1002/bjs.4455]

58 **Wong J**, Kelly KJ, Mittra A, Gonen M, Allen P, Fong Y, Coit D. Rt-PCR increases detection of submicroscopic peritoneal metastases in gastric cancer and has prognostic significance. *J Gastrointest Surg* 2012; **16**: 889-96; discussion 896 [PMID: 22362071 DOI: 10.1007/s11605-012-1845-2]

59 **Kishi K**, Fujiwara Y, Yano M, Inoue M, Miyashiro I, Motoori M, Shingai T, Gotoh K, Takahashi H, Noura S, Yamada T, Ohue M, Ohigashi H, Ishikawa O. Staging laparoscopy using ALA-mediated photodynamic diagnosis improves the detection of peritoneal metastases in advanced gastric cancer. *J Surg Oncol* 2012; **106**: 294-298 [PMID: 22389064 DOI: 10.1002/jso.23075]

60 **Murayama Y**, Ichikawa D, Koizumi N, Komatsu S, Shiozaki A, Kuriu Y, Ikoma H, Kubota T, Nakanishi M, Harada Y, Fujiwara H, Okamoto K, Ochiai T, Kokuba Y, Takamatsu T, Otsuji E. Staging fluorescence laparoscopy for gastric cancer by using 5-aminolevulinic acid. *Anticancer Res* 2012; **32**: 5421-5427 [PMID: 23225446]

61 **Peng Q**, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. *Cancer* 1997; **79**: 2282-2308 [PMID: 9191516]

62 **Krammer B**, Plaetzer K. ALA and its clinical impact, from bench to bedside. *Photochem Photobiol Sci* 2008; **7**: 283-289 [PMID: 18389144 DOI: 10.1039/b712847a]

63 **Zöpf T**, Schneider AR, Weickert U, Riemann JF, Arnold JC. Improved preoperative tumor staging by 5-aminolevulinic acid induced fluorescence laparoscopy. *Gastrointest Endosc* 2005; **62**: 763-767 [PMID: 16246693 DOI: 10.1016/j.gie.2005.05.020]

64 **Nagy KK**, Roberts RR, Joseph KT, Smith RF, An GC, Bokhari F, Barrett J. Experience with over 2500 diagnostic peritoneal lavages. *Injury* 2000; **31**: 479-482 [PMID: 10908739]

65 **Mezhir JJ**, Posner MC, Roggin KK. Prospective clinical trial of diagnostic peritoneal lavage to detect positive peritoneal cytology in patients with gastric cancer. *J Surg Oncol* 2013; **107**: 794-798 [PMID: 23532564 DOI: 10.1002/jso.23328]

66 **Cui J**, Li F, Wang G, Fang X, Puett JD, Xu Y. Gene-expression signatures can distinguish gastric cancer grades and stages. *PLoS One* 2011; **6**: e17819 [PMID: 21445269 DOI: 10.1371/journal.pone.0017819]

67 **Marrelli D**, De Stefano A, de Manzoni G, Morgagni P, Di Leo A, Roviello F. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. *Ann Surg* 2005; **241**: 247-255 [PMID: 15650634 DOI: 00000658-200502000-00009]

68 **Kattan MW**, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. *J Clin Oncol* 2003; **21**: 3647-3650 [PMID: 14512396 DOI: 10.1200/JCO.2003.01.240JCO.2003.01.240]

69 **Kologlu M**, Kama NA, Reis E, Doganay M, Atli M, Dolapci M. A prognostic score for gastric cancer. *Am J Surg* 2000; **179**: 521-526 [PMID: 11004344]

70 **Chen Y**, Mou L. A risk score system to preoperatively predict TNM stages in gastric cancer. *Am J Clin Oncol* 2011; **34**: 130-134 [PMID: 20375834 DOI: 10.1097/COC.0b013e3181d31eeb]

**P-Reviewers:** Elbahrawy A **S-Editor:** Ding Y **L-Editor: E-Editor:**